Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model

Texto completo
Autor(es):
Pereira, Cristiano Goncalves [1] ; Lavoie, Joao Ricardo [2] ; Garces, Edwin [2] ; Basso, Fernanda [1] ; Dabic, Marina [3, 4] ; Porto, Geciane Silveira [1] ; Daim, Tugrul [2, 5]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Sch Econ Business Adm & Accounting, Ribeirao Preto, SP - Brazil
[2] Portland State Univ, Engn & Technol Management Dept, Portland, OR 97207 - USA
[3] Univ Zagreb, Fac Econ & Business, Zagreb - Croatia
[4] Nottingham Trent Univ, Dept Management, Nottingham - England
[5] Natl Res Univ Higher Sch Econ, Inst Stat Studies & Econ Knowledge, Lab Econ Innovat, Moscow - Russia
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE; v. 139, p. 185-199, FEB 2019.
Citações Web of Science: 2
Resumo

Therapeutic monoclonal antibodies (mAbs) market is strongly contributing to the rising growth of the biotechnology industry. Despite the increasing number of inventions over time, a few therapeutic mAbs are currently marketed. This paper focuses on developing an emerging score to select/rank promising therapeutic mAbs patents, based on a hierarchical decision model using expert's opinion. Six attributes related to each factor concerning patent status, patent owner's profile and mAbs medical relevance were analyzed. The desirability levels of each attribute were also assessed. Our data shows the medical relevance factor as the most important, contributing 50% of the emerging score. Among the attributes, the most important under patent status was proper geographic coverage and wider patent scope; for organization's profile was the preexistence of approved drugs; and for medical relevance, the clinical phase performance. A group of 1053 patents related to therapeutic mAb were scored, and the most promising were concerning combination therapy using immune checkpoint inhibitors. The study has managerial implications related to patent portfolio management and patent valuation, and provides instructions to rank mAbs patents according to the emerging score defined by attribute's importance in order to improve the identification of future innovations pathways. (AU)

Processo FAPESP: 14/22500-8 - Identificação de tecnologias promissoras no setor da biotecnologia vermelha baseado em análises de patentes
Beneficiário:Cristiano Gonçalves Pereira
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 15/13816-4 - Produtividade científica e tecnológica das infraestruturas de pesquisa brasileiras
Beneficiário:Sérgio Kannebley Júnior
Linha de fomento: Auxílio à Pesquisa - Regular